Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Flucytosine + TG6002 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Flucytosine | Ancobon | 5-FC | ||
TG6002 | TG-6002|TG 6002|Oncolytic FCU1-expressing TK-RR-deleted Vaccinia Virus TG6002 | TG6002 is an engineered vaccinia virus that expresses the FCU1 gene and includes deletions of the viral genes J2R and I4L, which may lead to increased killing of tumor cells (PMID: 31011628). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03294486 | Phase Ib/II | Flucytosine + TG6002 | Safety and Efficacy of the ONCOlytic VIRus Armed for Local Chemotherapy, TG6002/5-FC, in Recurrent Glioblastoma Patients (ONCOVIRAC) | Unknown status | FRA | 0 |
NCT04194034 | Phase Ib/II | Flucytosine + TG6002 | Study of Intrahepatic Arterial Infusion of TG6002 in Combination With 5-FC in Patients With Metastatic Colorectal Cancer | Terminated | GBR | FRA | 0 |
NCT03724071 | Phase Ib/II | Flucytosine + TG6002 | Study of TG6002 (VV TK-RR-FCU1) in Combination With 5-FC in Patients With Advanced Gastro-intestinal Tumors. | Terminated | FRA | ESP | BEL | 0 |